Author Ziepert, Marita

1 to 20 of 63 Items
  • 2023 | Journal Article
    ​ ​Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R) - CHOP​
    Bewarder, M.; Kaddu-Mulindwa, D.; Kos, I. A.; Lesan, V.; Held, G.; Poeschel, V. & Thurner, L. et al.​ (2023) 
    Haematologica,.​ DOI: https://doi.org/10.3324/haematol.2022.282126 
    ​Details  DOI 
  • 2023 | Journal Article
    ​ ​Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study​
    Thurner, L.; Ziepert, M.; Berdel, C.; Schmidt, C.; Borchmann, P.; Kaddu-Mulindwa, D. & Viardot, A. et al.​ (2023) 
    HemaSphere, 7(7) art. e904​.​ DOI: https://doi.org/10.1097/HS9.0000000000000904 
    ​Details  DOI 
  • 2023 | Journal Article
    ​ ​Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial​
    Held, G.; Thurner, L.; Poeschel, V.; Ott, G.; Schmidt, C.; Christofyllakis, K. & Viardot, A. et al.​ (2023) 
    HemaSphere, 7(7) art. e917​.​ DOI: https://doi.org/10.1097/HS9.0000000000000917 
    ​Details  DOI 
  • 2022 | Journal Article
    ​ ​KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials​
    Kaddu-Mulindwa, D.; Altmann, B.; Robrecht, S.; Ziepert, M.; Regitz, E.; Tausch, E. & Held, G. et al.​ (2022) 
    The Lancet Haematology, 9(2) pp. e133​-e142​.​ DOI: https://doi.org/10.1016/S2352-3026(21)00369-0 
    ​Details  DOI 
  • 2022 | Journal Article
    ​ ​First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial​
    Braulke, F.; Zettl, F.; Ziepert, M.; Viardot, A.; Kahl, C.; Prange-Krex, G. & Korfel, A. et al.​ (2022) 
    HemaSphere, 6(12) art. e808​.​ DOI: https://doi.org/10.1097/HS9.0000000000000808 
    ​Details  DOI  WoS 
  • 2021 | Journal Article
    ​ ​Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial​
    Frontzek, F.; Ziepert, M.; Nickelsen, M.; Altmann, B.; Glass, B.; Haenel, M. & Truemper, L. et al.​ (2021) 
    The Lancet Haematology, 8(4) pp. e267​-e277​.​ DOI: https://doi.org/10.1016/S2352-3026(21)00022-3 
    ​Details  DOI 
  • 2021 | Journal Article
    ​ ​The “Burkitt-like” immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS​
    Hüttl, K. S.; Staiger, A. M.; Richter, J.; Ott, M. M.; Kalmbach, S.; Klapper, W. & Biesdorf, A.-S. et al.​ (2021) 
    Virchows Archiv,.​ DOI: https://doi.org/10.1007/s00428-021-03050-4 
    ​Details  DOI 
  • 2021 | Journal Article | Research Paper
    ​ ​Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma​
    Nordmo, C.; Glehr, G.; Altenbuchinger, M. ; Spang, R.; Ziepert, M.; Horn, H. & Staiger, A. M. et al.​ (2021) 
    Leukemia & Lymphoma, 62(5) pp. 1107​-1115​.​ DOI: https://doi.org/10.1080/10428194.2020.1861268 
    ​Details  DOI  PMID  PMC 
  • 2020 | Journal Article
    ​ ​A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL​
    Schmitz, N.; Truemper, L. H; Bouabdallah, K.; Ziepert, M.; Leclerc, M.; Cartron, G. & Jaccard, A. et al.​ (2020) 
    Blood,.​ DOI: https://doi.org/10.1182/blood.2020008825 
    ​Details  DOI 
  • 2020 | Journal Article
    ​ ​A 70% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a high-risk group of patients​
    Ziepert, M.; Lazzi, S.; Santi, R.; Vergoni, F.; Granai, M.; Mancini, V. & Staiger, A. et al.​ (2020) 
    Haematologica, 105(11) pp. 2667​-2670​.​ DOI: https://doi.org/10.3324/haematol.2019.235556 
    ​Details  DOI 
  • 2020 | Journal Article
    ​ ​Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial​
    Wulf, G. G. ; Altmann, B.; Ziepert, M.; D’Amore, F.; Held, G.; Greil, R. & Tournilhac, O. et al.​ (2020) 
    Leukemia,.​ DOI: https://doi.org/10.1038/s41375-020-0838-5 
    ​Details  DOI 
  • 2020 | Journal Article | Research Paper | 
    ​ ​Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group​
    Høhloch, K. ; Ziepert, M.; Trümper, L. ; Buske, C.; Held, G.; Poeschel, V. & Chapuy, B.  et al.​ (2020) 
    eJHaem, 1(1) pp. 181​-187​.​ DOI: https://doi.org/10.1002/jha2.61 
    ​Details  DOI 
  • 2020 | Journal Article | 
    ​ ​Age-dependent increase of treatment-related mortality in older patients with aggressive B cell lymphoma: analysis of outcome, treatment feasibility, and toxicity in 1171 elderly patients with aggressive B cell lymphoma—data from phase II and III trials of the DSHNHL (German High-Grade Non-Hodgkin’s Lymphoma Study Group)​
    Zettl, F.; Ziepert, M.; Altmann, B.; Zeynalova, S.; Held, G.; Pöschel, V. & Hohloch, K.  et al.​ (2020) 
    Annals of Hematology, 100(4) pp. 1031​-1038​.​ DOI: https://doi.org/10.1007/s00277-020-04345-3 
    ​Details  DOI 
  • 2019 | Journal Article
    ​ ​Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial​
    Poeschel, V.; Held, G.; Ziepert, M.; Witzens-Harig, M.; Holte, H.; Thurner, L. & Borchmann, P. et al.​ (2019) 
    The Lancet, 394(10216) pp. 2271​-2281​.​ DOI: https://doi.org/10.1016/S0140-6736(19)33008-9 
    ​Details  DOI 
  • 2019 | Journal Article
    ​ ​A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL​
    Staiger, A. M.; Altenbuchinger, M. ; Ziepert, M.; Kohler, C.; Horn, H.; Huttner, M. & Hüttl, K. S. et al.​ (2019) 
    Leukemia, 34(2) pp. 543​-552​.​ DOI: https://doi.org/10.1038/s41375-019-0573-y 
    ​Details  DOI 
  • 2019 | Journal Article
    ​ ​Conventional Immunochemotherapy (R-CHOEP) Vs High-Dose Immunochemotherapy (R-MegaCHOEP) in Younger Patients with High-Risk Aggressive B-Cell Lymphoma: 10-Year Long-Term Follow-up of a German Lymphoma Alliance (GLA) Study​
    Frontzek, F.; Ziepert, M.; Nickelsen, M.; Altmann, B.; Glass, B.; Hänel, M. & Truemper, L. et al.​ (2019) 
    Blood, 134(Supplement_1) pp. 1589​-1589​.​ DOI: https://doi.org/10.1182/blood-2019-123637 
    ​Details  DOI 
  • 2019 | Journal Article
    ​ ​Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)​
    Zettl, F.; Braulke, F.; Ziepert, M.; Viardot, A.; Kahl, C.; Prange-Krex, G. & Korfel, A. et al.​ (2019) 
    Blood, 134(Supplement_1) pp. 4073​-4073​.​ DOI: https://doi.org/10.1182/blood-2019-122948 
    ​Details  DOI 
  • 2019 | Journal Article | 
    ​ ​The impact of SOCS1 mutations in diffuse large B‐cell lymphoma​
    Mellert, K.; Martin, M.; Lennerz, J. K.; Lüdeke, M.; Staiger, A. M.; Kreuz, M. & Löffler, M. et al.​ (2019) 
    British Journal of Haematology, 187(5) pp. 627​-637​.​ DOI: https://doi.org/10.1111/bjh.16147 
    ​Details  DOI  PMID  PMC 
  • 2018 | Journal Article
    ​ ​Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant​
    d'Amore, F.; Leppä, S.; Silva, M. G. da; Relander, T.; Lauritzsen, G. F.; Brown, P. D. N. & Pezzutto, A. et al.​ (2018) 
    Blood, 132(Supplement 1) pp. 998​-998​.​ DOI: https://doi.org/10.1182/blood-2018-99-110429 
    ​Details  DOI 
  • 2018 | Journal Article
    ​ ​A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group​
    Staiger, A. M.; Altenbuchinger, M.; Ziepert, M.; Kohler, C.; Horn, H.; Huttner, M. & Huettl, K. et al.​ (2018) 
    Blood, 132(Supplement 1) pp. 343​-343​.​ DOI: https://doi.org/10.1182/blood-2018-99-112450 
    ​Details  DOI 

Researcher

Göttingen All

Sort

issue date

ASC DESC

Items per Page

10 20 50 100